Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 13Breast Neoplasms 11Carcinoma, Transitional Cell 6Carcinoma, Non-Small-Cell Lung 5Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 3Small Cell Lung Carcinoma 2Urothelial Bladder Carcinoma 1Salivary Gland Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Prostatic Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Lung Diseases 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Liver Failure 1HRD Cancer 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Small Cell 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

veliparib 1sacituzumab govitecan 1Taxes 1Raltegravir Potassium 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Failure × sacituzumab govitecan × 90 days × Clear all
NCT04617522 2026-06-02

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Gilead Sciences

Phase 1 Recruiting
30 enrolled

Neoplasm Metastasis, Liver Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡